vs
汉瑞祥（HSIC）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
汉瑞祥的季度营收约是Roper Technologies的1.6倍（$3.4B vs $2.1B），Roper Technologies净利率更高（15.8% vs 2.9%，领先12.9%），Roper Technologies同比增速更快（11.3% vs 7.7%），Roper Technologies自由现金流更多（$507.0M vs $338.0M），过去两年Roper Technologies的营收复合增速更高（10.5% vs 4.1%）
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
HSIC vs ROP — 直观对比
营收规模更大
HSIC
是对方的1.6倍
$2.1B
营收增速更快
ROP
高出3.6%
7.7%
净利率更高
ROP
高出12.9%
2.9%
自由现金流更多
ROP
多$169.0M
$338.0M
两年增速更快
ROP
近两年复合增速
4.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.4B | $2.1B |
| 净利润 | $101.0M | $331.0M |
| 毛利率 | 30.9% | 69.4% |
| 营业利润率 | 4.7% | 27.2% |
| 净利率 | 2.9% | 15.8% |
| 营收同比 | 7.7% | 11.3% |
| 净利润同比 | 7.4% | 53.7% |
| 每股收益（稀释后） | $0.85 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSICROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $3.4B | $2.1B | ||
| Q3 25 | $3.3B | $2.0B | ||
| Q2 25 | $3.2B | $1.9B | ||
| Q1 25 | $3.2B | $1.9B | ||
| Q4 24 | $3.2B | $1.9B | ||
| Q3 24 | $3.2B | $1.8B | ||
| Q2 24 | $3.1B | $1.7B |
净利润HSICROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $101.0M | $428.4M | ||
| Q3 25 | $101.0M | $398.5M | ||
| Q2 25 | $86.0M | $378.3M | ||
| Q1 25 | $110.0M | $331.1M | ||
| Q4 24 | $94.0M | $462.3M | ||
| Q3 24 | $99.0M | $367.9M | ||
| Q2 24 | $104.0M | $337.1M |
毛利率HSICROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 30.9% | 69.5% | ||
| Q3 25 | 30.7% | 69.5% | ||
| Q2 25 | 31.4% | 69.2% | ||
| Q1 25 | 31.6% | 68.7% | ||
| Q4 24 | 31.1% | 68.3% | ||
| Q3 24 | 31.3% | 69.2% | ||
| Q2 24 | 32.5% | 69.5% |
营业利润率HSICROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | 4.7% | 28.6% | ||
| Q3 25 | 4.9% | 28.4% | ||
| Q2 25 | 4.7% | 28.2% | ||
| Q1 25 | 5.5% | 27.9% | ||
| Q4 24 | 4.9% | 28.0% | ||
| Q3 24 | 4.9% | 28.1% | ||
| Q2 24 | 5.1% | 28.8% |
净利率HSICROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | 2.9% | 20.8% | ||
| Q3 25 | 3.0% | 19.8% | ||
| Q2 25 | 2.7% | 19.5% | ||
| Q1 25 | 3.5% | 17.6% | ||
| Q4 24 | 2.9% | 24.6% | ||
| Q3 24 | 3.1% | 20.8% | ||
| Q2 24 | 3.3% | 19.6% |
每股收益（稀释后）HSICROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.85 | $3.97 | ||
| Q3 25 | $0.84 | $3.68 | ||
| Q2 25 | $0.70 | $3.49 | ||
| Q1 25 | $0.88 | $3.06 | ||
| Q4 24 | $0.75 | $4.29 | ||
| Q3 24 | $0.78 | $3.40 | ||
| Q2 24 | $0.80 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.0M | $382.9M |
| 总债务越低越好 | $2.3B | $9.7B |
| 股东权益账面价值 | $3.2B | $18.8B |
| 总资产 | $11.2B | $34.6B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资HSICROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $156.0M | $297.4M | ||
| Q3 25 | $136.0M | $320.0M | ||
| Q2 25 | $145.0M | $242.4M | ||
| Q1 25 | $127.0M | $372.8M | ||
| Q4 24 | $122.0M | $188.2M | ||
| Q3 24 | $126.0M | $269.6M | ||
| Q2 24 | $138.0M | $251.5M |
总债务HSICROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $2.3B | $9.3B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.8B | $7.6B | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — |
股东权益HSICROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $3.2B | $19.9B | ||
| Q3 25 | $3.4B | $20.0B | ||
| Q2 25 | $3.4B | $19.6B | ||
| Q1 25 | $3.3B | $19.2B | ||
| Q4 24 | $3.4B | $18.9B | ||
| Q3 24 | $3.5B | $18.5B | ||
| Q2 24 | $3.5B | $18.1B |
总资产HSICROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $11.2B | $34.6B | ||
| Q3 25 | $11.1B | $34.6B | ||
| Q2 25 | $10.9B | $33.2B | ||
| Q1 25 | $10.5B | $31.4B | ||
| Q4 24 | $10.2B | $31.3B | ||
| Q3 24 | $10.6B | $31.6B | ||
| Q2 24 | $10.3B | $29.8B |
负债/权益比HSICROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.71× | 0.47× | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | 0.54× | 0.40× | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $381.0M | — |
| 自由现金流经营现金流 - 资本支出 | $338.0M | $507.0M |
| 自由现金流率自由现金流/营收 | 9.8% | 24.2% |
| 资本支出强度资本支出/营收 | 1.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.77× | — |
| 过去12个月自由现金流最近4个季度 | $573.0M | — |
8季度趋势，按日历期对齐
经营现金流HSICROP
| Q1 26 | — | — | ||
| Q4 25 | $381.0M | $738.0M | ||
| Q3 25 | $174.0M | $869.5M | ||
| Q2 25 | $120.0M | $404.1M | ||
| Q1 25 | $37.0M | $528.7M | ||
| Q4 24 | $204.0M | $722.2M | ||
| Q3 24 | $151.0M | $755.4M | ||
| Q2 24 | $296.0M | $384.1M |
自由现金流HSICROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $338.0M | — | ||
| Q3 25 | $141.0M | — | ||
| Q2 25 | $88.0M | — | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $168.0M | — | ||
| Q3 24 | $117.0M | — | ||
| Q2 24 | $259.0M | — |
自由现金流率HSICROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 9.8% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 8.3% | — |
资本支出强度HSICROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.3% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 1.2% | — |
现金转化率HSICROP
| Q1 26 | — | — | ||
| Q4 25 | 3.77× | 1.72× | ||
| Q3 25 | 1.72× | 2.18× | ||
| Q2 25 | 1.40× | 1.07× | ||
| Q1 25 | 0.34× | 1.60× | ||
| Q4 24 | 2.17× | 1.56× | ||
| Q3 24 | 1.53× | 2.05× | ||
| Q2 24 | 2.85× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
ROP
暂无分部数据
